Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2018 09:47 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Congratulates Founder James P. Allison, Ph.D., for 2018 Nobel Prize in Physiology or Medicine

Award Recognizes Achievements in Cancer Immunotherapy CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing...
September 25, 2018 16:15 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics to Present at Upcoming Investor Conferences in October

CAMBRIDGE, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
September 06, 2018 16:15 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that...
August 21, 2018 16:15 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Appoints Jolie M. Siegel as General Counsel

CAMBRIDGE, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the...
August 06, 2018 16:15 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights

– Successfully completed initial public offering, raising $100 million in gross proceeds – – Significant progress across platform and portfolio of vaccine and T-cell programs – – Enrollment...
June 29, 2018 16:15 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Announces Closing of Initial Public Offering

CAMBRIDGE, Mass., June 29, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the...
June 26, 2018 18:56 ET | Source: Neon Therapeutics, Inc.

Neon Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the...